AVS Revolutionizes Arterial Disease Treatment with New Headquarters in Boston's Seaport District

Boston's Seaport District welcomes AVS as it opens its global headquarters to support its revolutionary PIVL™ therapy for arterial disease. The new 9,365-square-foot facility in the heart of innovation will serve as a hub for research, development, and collaboration.

As AVS aims for regulatory approval in the U.S., the company's Chairman of the Board, Mark Toland, highlights the advantages of being situated in one of the nation's most vibrant hotbeds for innovation. The new space is expected to facilitate the company's growth in bringing the next generation intravascular lithotripsy therapy to both peripheral and coronary artery disease patients.

Equipped with state-of-the-art technology, the headquarters spans 3,500 square feet and includes dedicated research and development areas, testing facilities, and assembly and packaging spaces. Located at 451 D Street, a historic building renovated in 2016, the headquarters offers easy access to transportation and major airports.

AVS has experienced significant growth since January 2023, reaching several milestones, including the appointment of Sean Gilligan as the Chief Operating Officer. Gilligan's over 30 years of executive leadership experience in the medical device industry, including 15 years at Boston Scientific, will contribute to AVS's continued success.

In April, AVS secured $28.8 million in Series B financing, led by BioStar Capital and CUE Growth Partners. The funds have supported ongoing clinical trials focusing on peripheral arteries. Additionally, AVS successfully completed the first-in-human clinical trial for peripheral vascular cases, with full trial results expected to be presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in October.

The opening of the new headquarters is a testament to AVS's progress and commitment to bringing its innovative solution to the market. Gilligan highlights the company's accelerated capabilities and hybrid manufacturing strategy, which leverages internal resources and partnerships with experienced contract manufacturers for an efficient path to market.

To learn more about AVS and the groundbreaking PULSE IVL System, visit [www.avspulse.com](https://www.avspulse.com).

About AVS:

AVS is an early-stage medical device company founded in 2018 by Dr. Hitinder Gurm and Dr. Robert Chisena. The company focuses on safely and effectively treating severely calcified arterial disease. The Pulse IVL System, developed by AVS, utilizes a novel pulsatile mechanism to shatter calcium and expand narrowed vessels, all with a single device. For more information on pulsatile intravascular lithotripsy, visit [www.avspulse.com](https://www.avspulse.com).

Disclaimer: The Pulse Peripheral Intravascular Lithotripsy (IVL) System is currently in development and has not yet received clearance for commercial distribution in any country. Its availability in the future cannot be guaranteed.